+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 2Years - 40Years
All Genders
ID05577754

Assessment of the Efficacy and Safety of Alpelisib BYL719 in Pediatric and Adult Patients With Megalencephaly-Capillary Malformation Polymicrogyria Syndrome MCAP

Led by Centre Hospitalier Universitaire Dijon · Updated on 2026-02-24

20

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of alpelisib BYL719 in both children and adults diagnosed with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome MCAP, a neurodevelopmental disorder. This Phase II trial includes a 6-month double-blind, placebo-controlled period followed by an open-label treatment phase, aiming to provide a total of 24 months of treatment. The study focuses on assessing behavioral and neurological improvements and monitoring safety in participants aged 2 to 40 years. Participants will be randomly assigned to receive either alpelisib or a matching placebo once daily during the first 6 months. After this period, all participants enter an open-label phase where they receive alpelisib for up to 24 months. Dose adjustments may occur for children aged 5 and older depending on their response and tolerance. Optional lumbar punctures and blood samples will be collected between 6 and 24 months to analyze drug levels. Throughout the study, participants will be followed monthly at local centers with regular clinical, biological, neuropsychological, and functional assessments at baseline and every 6 months. Brain volumetric MRI scans will be performed at the start and after 24 months. The main outcome measured is the proportion of participants showing improvement on the Vineland II Adaptive Behavior Scale after 24 months. Safety and other neurological and quality of life measures will also be monitored. Participants may discontinue treatment early for toxicity, disease progression, or other reasons.

CONDITIONS

Brief Title

Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

Research Team

L

Laurence OLIVIER-FAIVRE

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here